



## ASX ANNOUNCEMENT

### ANAGENICS APPOINTS CEO

**SYDNEY, Tuesday, 1 March 2022: Anagenics Limited (ASX: AN1) (Company)** is pleased to advise that it has appointed Matthew Dudek as Acting Chief Executive Officer, effective 28 February 2022. Maria Halasz has resigned as CEO and Managing Director of Anagenics Limited, effective on the same date.

Matthew has been the Company's Group Financial Controller since the beginning of 2020. He is a graduate from the University of Sydney, B.Com (Accounting, Finance and Economics) and is a member of Chartered Accountants Australia and New Zealand. Since joining Anagenics Matthew has played a key role in the day-to-day management of the Company, has a deep knowledge of the business and a strong track record in implementing profit improvement initiatives and strategies.

Matthew will continue to be supported by a highly qualified senior executive team including Dr Dominic Burg as Chief Operating Officer and Carolyn Heath as General Manager Sales.

The priority of the Company is to build a profitable foundation by implementing near term cost optimization measures and, in parallel, capitalise on the growth potential of its technology, eCommerce and brands by pursuing a pipeline of white label partnerships and distribution opportunities.

"I am honoured to take over as Chief Executive Officer. Anagenics is an exciting company with strong intellectual property, highly differentiated products and global potential. I am looking forward to delivering on our objectives and leading our next stage of growth" said incoming CEO, Matthew Dudek.

"I am delighted to have a strong internal appointment and would like to welcome Matthew, on behalf of the Board, in his new role. I look forward to supporting him in delivering the Company to near term profitability" said Chairman Sandy Beard.

Approved for release by the Board of Directors.

#### **Investor Enquiries:**

Sandy Beard  
Chairman  
+61 412 308 263  
info@anagenics.com

#### **Anagenics Limited (ASX: AN1)**

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary brands of differentiated, clinically validated anti-aging and solutions and the exclusive distribution of Australian and international cosmeceutical and wellness brands. For further information, please see [www.anagenics.com](http://www.anagenics.com) [www.evolisproducts.com.au](http://www.evolisproducts.com.au) and [www.blccosmetics.com](http://www.blccosmetics.com).

#### **Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.



**APPENDIX:  
SUMMARY OF MATTHEW DUDEK'S KEY EMPLOYMENT TERMS**

Base Salary: \$250,000 excluding superannuation

Term: 12 months from the effective date of 28 February 2022. During this period the Company and Matthew may determine a permanent CEO role is suitable and put in place a new contract

Incentives: Matthew will be invited to participate in the Company's short-term and long-term incentive schemes to be agreed by the Board of Directors